BioLineRX
BLRX
29 hedge funds and large institutions have $2.46M invested in BioLineRX in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 5 closing their positions.
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
25% more capital invested
Capital invested by funds: $1.97M → $2.46M (+$490K)
12% more funds holding
Funds holding: 26 → 29 (+3)
0% more ownership
Funds ownership: 0% → 0% (+0%)
11% less call options, than puts
Call options by funds: $635K | Put options by funds: $715K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$353K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$257K |
| 3 |
VFA
Values First Advisors
Gray,
Tennessee
|
+$81.2K |
| 4 |
RG
Rathbones Group
Liverpool,
United Kingdom
|
+$66.9K |
| 5 |
AMBIA
Allen Mooney & Barnes Investment Advisors
Thomasville,
Georgia
|
+$42K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$258K |
| 2 |
Renaissance Technologies
New York
|
-$157K |
| 3 |
Morgan Stanley
New York
|
-$143K |
| 4 |
PAM
PVG Asset Management
Golden,
Colorado
|
-$98.6K |
| 5 |
GVAG
Great Valley Advisor Group
Wilmington,
Delaware
|
-$20K |
BLRX Hedge Fund Activity: Q3 2023 in Review
29 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q3 2023, worth a combined $2.46M — up 25% from $1.97M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new BLRX positions and 5 closed out — a net gain of 3 holders — while 8 added to existing stakes and 6 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $353K. The largest seller was Citadel Advisors, cutting an estimated $258K.
- 29 institutional investors held BioLineRX (BLRX) as of Q3 2023, up from 26 in Q2 2023.
- Funds reported $2.46M of BioLineRX stock for Q3 2023, up 25% quarter-over-quarter.
- 8 funds opened new BioLineRX positions in Q3 2023 and 5 closed out, a net change of +3 holders.
- The largest BioLineRX buyer in Q3 2023 was Sabby Management, an estimated $353K added.
- The largest BioLineRX seller in Q3 2023 was Citadel Advisors, an estimated $258K sold.
Based on aggregated 13F filings for Q3 2023.